Related Experiment Videos
Formulary management of ACE inhibitors
1Section of Pharmacy Practice, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Pharmacoeconomics
|November 3, 1996
Summary
Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs with similar benefits, but differences in pharmacokinetics, duration of action, and cost influence formulary decisions. Clinical efficacy, duration, and cost are key factors in selecting ACE inhibitors.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- A growing number of Angiotensin-Converting Enzyme (ACE) inhibitors are available.
- These drugs share similarities, necessitating careful evaluation for formulary decisions.
Purpose of the Study:
- To review the differences and similarities among ACE inhibitors.
- To guide formulary decisions based on clinical relevance, pharmacokinetics, and cost-effectiveness.
Main Methods:
- Review of existing literature on ACE inhibitor pharmacology, clinical trials, and cost-effectiveness.
- Analysis of pharmacokinetic properties, tissue specificity, and clinical outcomes.
Main Results:
- ACE inhibitors exhibit variations in bioconversion, distribution, elimination, and duration of action.
- Disease states like congestive heart failure (CHF) and renal insufficiency impact ACE inhibitor disposition.
- Efficacy differences often stem from study design or non-equipotent dosages; benefits are likely class effects.
- Adverse effects and drug interactions show minor differences.
- Cost and availability vary, influencing formulary choices.
- Longer-acting ACE inhibitors offer greater financial benefits in hypertension management.
Conclusions:
- ACE inhibitors are largely homogeneous, making selection challenging.
- Clinical efficacy, duration of action, and cost are primary considerations for formulary inclusion.
- While benefits are class effects, specific agent selection requires careful consideration of individual patient factors and drug properties.